References

Allan, S., G. Kavanagh et al. (2004). The effect of inositol supplements on the psoriasis of patients taking lithium: A randomized, placebo-controlled trial. British Journal of Dermatology, 150: 966–969.

Arbiser, J., B. Govindarajaran et al. (2006). Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. Journal of Investigative Dermatology, 126(6): 1396–1402.

Ashcroft, D., A. Po et al. (2000). Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. British Medical Journal, 320(7240): 963–967.

British Association of Dermatologists (2007). Biologics Intervention Register. Retrieved 15 April 2009, from www.badbir.org.

British Medical Association and Royal Pharmaceutical Society of Great Britain (2008).

British National Formulary 55. Retrieved 17 March 2008, from www.bnf.org.

Camisa, C., Ed. (2004a). The clinical variants of psoriasis. In: Handbook of Psoriasis. Malden: Blackwell Publishing.

Camisa, C., Ed. (2004b). UVB phototherapy and coal tar. In: Handbook of Psoriasis. Malden: Blackwell Publishing.

Christophers, E. (2007). Comorbidities in psoriasis. Clinics in Dermatology, 25(6).

Cooper, E., R. Herd et al. (2000). A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clinical and Experimental Dermatology, 25(2): 111–114.

Datapharm (2009). Electronic Medicines Compendium. Retrieved 15 April 2009, from www.emc.medicines.org.

de Korte, J., J. Van Onselen et al. (2005). Quality of care in patients with psoriasis: An initial clinical study of an international disease management programme. Journal of the European Academy of Dermatology and Venereology, 19(1): 35–41.

Ersser, S., R. Penzer et al. (2000). Research report: Pruritus in psoriasis, School of Nursing and Midwifery, University of Southampton.

European Medicines Agency (2009). Press Release – European Medicines Agency recommends suspension of marketing authorisation of Raptiva (efalizumab). Retrieved 15 April 2009, from https://www. emea.europa.eu/humandocs/PDFs/EPAR/ raptiva/2085709en.pdf.

Fortes, C., S. Mastroeni et al. (2005). Relationship between smoking and clinical severity of psoriasis. Archives of Dermatology, 141(12): 1580–1584.

Franklin, S. and M. Glickman (1986). Lepra, psora, psoriasis. Journal of the American Academy of Dermatology, 14(5): 863–866.

Gelfand, J., A. Troxel et al. (2007). The risk of mortality in patients with psoriasis: Results from a population-based study. Archives of Dermatology, 143: 1493–1499.

Graham-Brown, R. and T. Burns (2006). Lecture Notes: Dermatology (9th edition). Oxford: Blackwell Science.

Griffiths, C., C. Clark et al. (2000). A systematic review of treatments for psoriasis. Health Technology Assessment, 4(1): 1–125.

Guenther, L., F. Cambazard et al. (2002). Efficacy and safety of a new combination of calcipotriol and betamethasone diproprionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double blind, vehicle-controlled clinical trial. British Journal of Dermatology, 147(2): 316–323.

Gulliver, W. (2008). Long-term prognosis in patients with psoriasis. British Journal of Dermatology, 159(Suppl 2): 2–9.

Hudson-Peacock, M., B. Diffey et al. (1994). Photoprotective action of emollients in ultraviolet therapy of psoriasis. British Journal of Dermatology, 130(3): 361–365.

Jackson, K., S. Maguire et al. (2007). Biologic therapies in psoriasis: The key role of the dermatology nurse specialist. Dermatological Nursing, 6(1): s1–s11.

Kreuger, J. (2002). The immunologic basis for the treatment of psoriasis with new biologic agents. Journal of the American Academy of Dermatology, 46(1): 1–23.

Lee, E. and J. Koo (2005). Modern modified ‘ultra’ Goeckerman therapy: A PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies. Journal of Dermatologic Treatment, 16(2): 102–107.

Naldi, L. and C. Griffiths (2005). Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. British Journal of Dermatology, 152: 597–615.
Naldi, L., L. Chatenoud et al. (2005). Cigarette smoking, body mass index and stressful life events as risk factors for psoriasis: Results from an Italian case control study. Journal of Investigative Dermatology, 125(1): 61–67.

National Institute for Clinical Excellence (2001). Referral Advice: A Guide to Appropriate Referral from General to Specialist Services. London: NICE.

National Institute for Health and Clinical Excellence (2006). Etanercept and Efalizumab for the Treatment of Adults with Psoriasis: NICE Technology Appraisal. London: NICE.


National Institute for Health and Clinical Excellence (2008a). Infliximab for the Treatment of Adults with Psoriasis: Single Technology Appraisal. London: NICE.

National Institute for Health and Clinical Excellence (2008b). Adalimumab for the Treatment of Adults with Psoriasis: Single Technology Appraisal. London: NICE.

Osborn, T. and W. Wilke (2004). Psoriatic arthritis. In: Camisa, C. (Ed.), Handbook of Psoriasis. Massachusetts: Blackwell Publishing.

Otman, S., C. Edwards et al. (2006). Modulation of ultraviolet (UV) transmission by emollients: Relevance to narrowband UVB phototherapy and psoralen plus UVA photochemotherapy. British Journal of Dermatology, 154(5): 963–968.

Rapp, S., S. Feldman et al. (1999). Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, 41(3(pt1)): 401–407.

Richards, H., D. Ray et al. (2005). Response of the hypothalamic–pituitary–adrenal axis to psychological stress in patients with psoriasis. British Journal of Dermatology, 153: 1114–1120.

Rim, J., J. Park et al. (2003). The efficacy of calcipotriol
acitretin combination therapy for psoriasis: Comparison with acitretin monotherapy. American Journal of Clinical Dermatology, 4(7): 507–510.

Roelofzen, J., K. Aben et al. (2007). Coal tar in dermatology. Journal of Dermatologic Treatment, 18(6): 329–334.

Smith, C., A. Anstey et al. (2005). British Association of Dermatologists Guidelines on the use of biological interventions in psoriasis in 2005. British Journal of Dermatology, 153: 486–497.

Sommer, D., S. Jenisch et al. (2006). Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Archives of Dermatological Research, 298(7): 321–328.

Streit, V., O. Wiedow et al. (1996). Treatment of psoriasis with polyethylene sheet bath PUVA. Journal of American Academy of Dermatology, 35(2): 208–210.
van de Kerkhof, P., P. van der Valk et al. (2006). A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: A randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. British Journal of Dermatology, 155(4): 800–807.

Veraldi, S., R. Caputo et al. (2006). Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology, 212(3): 235–237.

Weller, R., J.A.A. Hunter, J. Savin and M. Dahl (2008). Clinical Dermatology (4th edition). Oxford: Wiley-Blackwell.

Williams, H.C. (1997). Dermatology Health Care Needs Assessment. Oxford: Radcliffe Medical Press.

Woo, W. and K. McKenna (2003). Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: A prospective randomized placebo-controlled clinical trial. British Journal of Dermatology, 149(1): 146–150.